Skip to content
10-K

Annual Report

CytomX Therapeutics, Inc. CTMX

0000950170-25-034575

← back to feed
Filed
Mar 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 80.1M sh
Shares Diluted FY 2024 · Dec 31, 2023 73.81M sh
Capex FY 2024 · Dec 31, 2023 $840K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$56.04M
Cash And Equivalents FY 2024 · Dec 31, 2023 $17.17M
Current Liabilities FY 2024 · Dec 31, 2023 $155.91M
Total Liabilities FY 2024 · Dec 31, 2023 $249.24M
Current Assets FY 2024 · Dec 31, 2023 $182.94M
Total Assets FY 2024 · Dec 31, 2023 $201.79M
Sga Expense FY 2024 · Dec 31, 2023 $30.02M
Rd Expense FY 2024 · Dec 31, 2023 $77.68M
Net Income FY 2024 · Dec 31, 2023 −$569K
Operating Income FY 2024 · Dec 31, 2023 −$6.48M
Revenue FY 2024 · Dec 31, 2023 $101.21M
Stockholders Equity FY 2024 · Dec 31, 2022 −$85.75M